PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced ...

Less than a week after a deadly truck crash and fire led to the collapse of an elevated portion of I-95 in Northeast Philadelphia, crews have completed demolition of the crash site and have entered ...

EDDYSTONE, Pennsylvania (WPVI) -- As contractors finished the demolition of the damaged portion of Interstate 95, one expert believes the next step could be completed in a matter of weeks, and ...

Bitcoin (BTC) is showing signs of recovery. During such times, capital often rotates from BTC into altcoins. Altcoins with strong utility attract fast-moving investors. They tend to catch momentum ...

One of the new altcoins with a rapid growth rate valued at $0.35 has hit the 95% allocation and investors affirm that the remaining phase of the allocation process is moving at a faster time than ...

East Lyme — The $155 million reconstruction of Interstate 95 here has passed the halfway point, and in September it begins a new phase that shifts the current layout of the southbound lanes near Exit ...

Zenas Biopharma’s autoimmune drug candidate has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. The midstage MoonStone study saw 116 ...

The US Highway 95 lane expansion effort marked another milestone earlier today. Starting this month, a stretch of US Highway 95 from Rifle Range Road to the Wellton-Mohawk Canal Bridge is being ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ...

Fort Bend Independent School District has unveiled the next phase of the Sugar Land 95 Memorial, which includes an outdoor learning area and a memorial cemetery and is expected to be ready by 2025.

Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers ...